In trading on Monday, shares of Loews Corp. (Symbol: L) crossed below their 200 day moving average of $103.39, changing hands as low as $102.94 per share. Loews Corp. shares are currently trading down about 1.5% on the day. The chart below shows the one year performance of L s

AMD reportedly preparing new AM5 boards or chipsets for summer HWCooling.net

In trading on Monday, shares of Caleres Inc (Symbol: CAL) crossed below their 200 day moving average of $12.82, changing hands as low as $11.94 per share. Caleres Inc shares are currently trading off about 8.7% on the day. The chart below shows the one year performance of CAL

Plug Power press release ( PLUG ): Q1 Non-GAAP EPS of -$0.08 beats by $0.02 . Revenue of $163.51M (+22.3% Y/Y) beats by $23.75M . Revenue increased 22% year-over-year to $163.5 million, reflecting growth across material handling and electrolyzer businesses Shares -4% . More on Plug Power Plug Power's Inflection Point: From Cash Burn To Clean Energy Scale Plug Power: Some Progress But Major Headwinds Remain - Sell Plug Power: Improving Operations, Still A Hold For Me Quant snapshot: Beachbody, Deutsche Telekom among top-rated names as IceCure Medical, Fold Holdings lag Plug Power Q1 earnings preview: revenue growth in focus

格隆汇5月12日｜据以色列i24News：以色列北部启动无人机渗透警报。

DeepSeek-R1 hallucinates 14.3% per Vectara, 4x more than V3. The data signals risk for crypto AI agent tokens.

American Battery Technology press release ( ABAT ): Q1 Revenue of $7.8M. $38.5 million cash, balance as of end of quarter Includes $37.7 million in unrestricted and $0.8 million in restricted cash $7.1 million in Cost of Goods Sold, an 11% increase from the previous quarter $5.8 million cash cost of goods sold (non-GAAP1), with exclusion of non-cash expenses of depreciation and stock-based compensation $0.7 million in Gross Margin, ABTC’s first positive gross margin operations $2.0 million in Adjusted Gross Margin (non-GAAP1), with exclusion of non-cash expenses of depreciation and stock-based compensation More on American Battery Technology Seeking Alpha’s Quant Rating on American Battery Technology Historical earnings data for American Battery Technology Financial information for American Battery Technology

Lumentum Holdings Inc.（LITE）收涨17%，创2025年11月以来最大单日涨幅。

格隆汇5月12日｜美股周一收盘，道指初步收涨0.19%，标普500指数涨0.19%，纳指涨0.1%。英伟达(NVDA.O)、高通(QCOM.O)、英特尔(INTC.O)、美光科技(MU.O)和西部数据(WDC.O)均创下历史收盘新高。纳斯达克中国金龙指数收涨1%，百度(BIDU.O)涨3%。

The phrase, emerging from Southeast Asia, is the best way to describe the market action on Monday. The S&P 500 rose 0.2% while the tech-heavy Nasdaq was up 0.1%. Investors had seen the S&P 500 and Nasdaq finish at a record last week as well.

美股三大指数均小幅收涨，道指涨0.19%，标普500指数涨0.19%，纳指涨0.1%。其中，标普500指数、纳指续创新高。

谷歌母公司Alphabet收跌3%，创3月份以来最大单日跌幅。

Microsoft (MSFT) Targeted $92B Return from Early OpenAI Investment, Court Documents Show TipRanks

MILLBRAE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today reported first quarter 2026 financial results and provided updates on its lead clinical programs.

BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today reported financial results and business highlights for the first quarter ended March 31, 2026.

Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data

SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye” or the “Company”), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the first quarter ended March 31, 2026, along with recent business updates and anticipated milestones. “Since our March update, execution has focused on turning CBeyond into a Phase 2b-ready development program,” said Punit Dhillon, President & CEO of Skye. “We have now initiated enrollment of Cohort 1 of the CBeyond Expansion Study, executed the compatibility and in-use study with ENHANZE to support a practical high-volume subcutaneous approach, and engaged external development advisors to help pressure-test our target product profile, dose-selection rationale and Phase 2b trial design. Our objective in 2026 remains focused on defining the dose and exposure that can support a larger Phase 2b study evaluating nimacimab as a complementary add-on approach for GLP-1-experienced patients.”

NEWTOWN SQUARE, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent Company progress.

Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026

Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted agents

NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Silvercrest Asset Management Group Inc. (NASDAQ: SAMG) (the “Company” or “Silvercrest”) today reported the results of its operations for the quarter and year ended March 31, 2026.

Plug Power Reports Strong Q1 2026 Results with 22% Revenue Growth and 71% Margin Improvement Year over Year